Century Therapeutics, Inc. (NASDAQ:IPSC) Short Interest Up 6.4% in September

Century Therapeutics, Inc. (NASDAQ:IPSC - Get Free Report) saw a significant increase in short interest during the month of September. As of September 30th, there was short interest totalling 3,490,000 shares, an increase of 6.4% from the September 15th total of 3,280,000 shares. Based on an average daily trading volume, of 331,100 shares, the days-to-cover ratio is presently 10.5 days. Approximately 10.8% of the shares of the company are sold short.

Century Therapeutics Price Performance

Shares of IPSC stock traded up $0.07 during mid-day trading on Wednesday, hitting $1.57. The company had a trading volume of 157,907 shares, compared to its average volume of 248,864. Century Therapeutics has a 52-week low of $1.28 and a 52-week high of $5.51. The stock's 50 day moving average price is $1.62 and its 200-day moving average price is $2.47. The company has a market capitalization of $132.67 million, a P/E ratio of -0.69 and a beta of 1.36.

Century Therapeutics (NASDAQ:IPSC - Get Free Report) last released its earnings results on Thursday, August 8th. The company reported ($0.38) EPS for the quarter, topping the consensus estimate of ($0.50) by $0.12. Century Therapeutics had a negative net margin of 6,434.23% and a negative return on equity of 60.60%. The firm had revenue of $0.77 million for the quarter, compared to the consensus estimate of $0.55 million. On average, equities research analysts expect that Century Therapeutics will post -1.8 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on IPSC. Rodman & Renshaw initiated coverage on shares of Century Therapeutics in a report on Thursday, August 8th. They issued a "buy" rating and a $6.00 price objective on the stock. HC Wainwright lowered their price target on shares of Century Therapeutics from $11.00 to $9.00 and set a "buy" rating on the stock in a report on Thursday, August 15th.

Institutional Investors Weigh In On Century Therapeutics

Several large investors have recently bought and sold shares of IPSC. SG Americas Securities LLC bought a new stake in Century Therapeutics in the third quarter worth $27,000. Mirae Asset Global Investments Co. Ltd. bought a new stake in Century Therapeutics in the first quarter worth $47,000. Rhumbline Advisers increased its position in Century Therapeutics by 56.0% in the second quarter. Rhumbline Advisers now owns 52,466 shares of the company's stock worth $134,000 after purchasing an additional 18,828 shares during the last quarter. Dimensional Fund Advisors LP increased its position in Century Therapeutics by 141.7% in the second quarter. Dimensional Fund Advisors LP now owns 75,315 shares of the company's stock worth $192,000 after purchasing an additional 44,155 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its position in Century Therapeutics by 110.1% in the second quarter. Bank of New York Mellon Corp now owns 149,000 shares of the company's stock worth $380,000 after purchasing an additional 78,088 shares during the last quarter. Institutional investors own 50.20% of the company's stock.

Century Therapeutics Company Profile

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.